Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial Meeting Abstract
| Authors: | Motzer, R. J.; Bex, A.; Russo, P.; Tomita, Y.; Cutuli, H.; Rojas, C.; Gross-Goupil, M.; Schinzari, G.; Melichar, B.; Barthelemy, P.; Garcia, A. R.; Sosman, J. A.; Grimm, M. O.; Goh, J. C.; Suárez, C.; Kollmannsberger, C. K.; Simsek, B.; Spiridigliozzi, J.; Lee, C. W.; Grünwald, V. |
| Abstract Title: | Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial |
| Meeting Title: | 2024 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2024 Jan 25-27 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-02-01 |
| Language: | English |
| ACCESSION: | WOS:001266676900670 |
| DOI: | 10.1200/JCO.2024.42.4_suppl.LBA358 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA358 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
